+++ Umfrage: ETFs werden als Anlageinstrument immer beliebter - was ist Ihre Meinung? +++ -w-
News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
03.11.2016 08:00:11

DGAP-News: Neovacs SA

DGAP-News: Neovacs to attend Jefferies 2016 London Healthcare Conference November 16 & 17, 2016

DGAP-News: Neovacs S.A. / Key word(s): Conference Neovacs to attend Jefferies 2016 London Healthcare Conference November 16 & 17, 2016

03.11.2016 / 08:00 The issuer is solely responsible for the content of this announcement.


(Anzeige)Passende neue Barrier Reverse Convertibles


Neovacs to attend Jefferies 2016 London Healthcare Conference November 16 & 17, 2016

Paris and Boston, November 3rd, 2016 - Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at the Jefferies 2016 London Healthcare Conference taking place November 16-17 at the Waldorf Hilton in London, UK.

This Conference is the largest healthcare meeting in Europe dedicated to companies from around the world from the biotechnology, pharmaceutical, generic, consumer health, medical technology and Healthcare Service sectors. Last year, the Jefferies conference hosted over 300 participating companies, 1,200 attendees and 3,700 business-to-business and investor meetings.

The two-day event will include concurrent tracks of company presentations, thematic panel discussions, and 1x1/small-group meetings. This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.

About Neovacs Listed on Alternext Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNa-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life- long diseases. www.neovacs.fr

Contacts NEOVACS - Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 14 cmasson@neovacs.com

Investor Relations / Financial Communications Germany - MC Services Raimund Gabriel +49-89-21-02-28-30 raimund.gabriel@mc-services.eu

Press / U.S. Inquiries - The Ruth Group Lee Roth / Joseph Green +1-646-536-7012 / 7013 lroth@theruthgroup.com / jgreen@theruthgroup.com


03.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de


Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt End of News DGAP News Service ---------------------------------------------------------------------------

516729 03.11.2016

Nachrichten zu Neovacs SAmehr Nachrichten

DGAP-News: Neovacs SA (EQS Group)
DGAP-News: Neovacs SA (EQS Group)
DGAP-News: Neovacs SA (EQS Group)
DGAP-News: Neovacs SA (EQS Group)
Original-Research: Neovacs S.A. (von GBC AG): BUY (dpa-afx)
Original-Research: Neovacs S.A. (von GBC AG): Kaufen (dpa-afx)
DGAP-News: Neovacs SA (EQS Group)
DGAP-News: Neovacs SA (EQS Group)